I
t is now a decade since the discovery of the angiotensin I (Ang I)-converting enzyme homolog, ACE2 [EC 3.4.15.1] . During this period, efforts toward the characterization of this enzyme have provided greater insights into the renin-angiotensin-aldosterone system. The ongoing studies provoked more questions, particularly regarding the role of the enzyme in the development and progression of hypertension and renal injury, as well as other pathologies including diabetes, heart failure, liver failure and pulmonary injury. In this issue of Hypertension Research, Kamilic et al. 1 determined the distribution, expression and activity of ACE2 within the kidney of two rat models of established hypertension and their normotensive controls. Although the reported localization of ACE2 within the kidney differs to some extent with other reports in the rat, the current study reveals no difference in ACE2 expression between the hypertensive and normotensive rats, suggesting that the enzyme may not contribute to the development of the hypertensive phenotype.
Both ACE and ACE2 are chloride-activated metallopeptidases that are primarily membrane bound and ubiquitously distributed in various tissues; however, ACE2 is a carboxypeptidase that hydrolyzes a single amino acid from the carboxyl end of peptides as opposed to the dipeptidylcarboxypeptidase properties of ACE. ACE inhibitors do not attenuate ACE2 activity, but may increase expression of the enzyme in certain circumstances. 2 Previous studies identified Ang I as the substrate for ACE2, most likely given the similar homology to ACE and the existing evidence for ACE-independent pathways. Indeed, Ang I was metabolized by the enzyme to the nonapeptide Ang-(1-9), but not directly to Ang II. Subsequently, kinetic studies revealed that the conversion of Ang II to Ang-(1-7) was the preferred pathway, with a B500-fold greater efficiency (kcat Km À1 ) than that for hydrolysis of Ang I to Ang-(1-9). Indeed, ACE2 exhibits a higher catalytic efficiency in comparison with other peptidases that generate Ang-(1-7) (Figure 1 ).
Various studies have revealed the importance of ACE2 to influence expression of Ang II and Ang-(1-7), particularly within the kidney. Transgenic mice with total knockout of ACE2 exhibit higher tissue levels of Ang II. 3, 4 Tikellis et al. 5 recently showed that in addition to enhanced Ang II levels in ACE2 À/À transgenic mice, the renal content of Ang-(1-7) was markedly lower, which clearly shows the direct utilization of Ang II by ACE2 as the precursor for Ang-(1-7) within the kidney. Induction of type 1 diabetes by streptozotocin is associated with lower ACE2 activity in the kidney, which primarily reflects reduced expression in proximal tubules and glomerulus. 5, 6 Induced diabetes in the ACE2-deficient mice reveals an exaggerated phenotype of renal injury (increased albuminuria) in comparison with the streptozotocin-trea- ted wild-type mice. In this regard, reninangiotensin system blockade by either an ACE inhibitor or an Ang II type I (AT1) receptor antagonist is less effective in the diabetic ACE2-deficient mice or after chronic treatment with an ACE2 inhibitor than the diabetic control mice. 5, 6 Moreover, Benter et al. 7 found that Ang-(1-7) or its nonpeptide receptor agonist, AVE0991, attenuates proteinuria and oxidative stress in hypertensive diabetic rats. These studies clearly implicate the importance of renal ACE2 and its product Ang-(1-7) in diabetes-induced renal injury. Although the influence of ACE2 in renal and cardiac injury has become more evident, the role of the enzyme in the regulation of blood pressure, particularly in hypertensive animals, is equivocal at this point. Crackower et al. 3 first reported that the ACE2 transgenic mice exhibited lower blood pressure than the wild-type mice; however, the reduced pressure likely reflects reduced cardiac output due to impaired cardiac function in older transgenic mice. Subsequent reports in other ACE2 À/À transgenic strains have revealed either no change or a slight increase in blood pressure with no evidence of cardiac ventricular dysfunction in younger mice. 4, 8 The Crackower study also showed reduced protein expression of ACE2 in the kidneys of several hypertensive models, including the spontaneously hypertensive rat (SHR), the stroke-prone SHR and the Sabra salt-sensitive rat. 3 Moreover, in fetal programmed hypertension, ACE2 activity in the proximal tubules and urine is markedly reduced without changes in renal ACE. 9 Tikellis et al. 10 confirmed the findings by Crackower in their study of the developmental expression of ACE2 in the SHR and the normotensive Wistar Kyoto (WKY) rats. ACE2 mRNA expression and enzyme activity were significantly reduced in the SHR kidneys at 6 weeks and 12 weeks as compared with WKY rats. However, systolic blood pressures were markedly higher in the SHR by 6 weeks of age, and the reduction in ACE2 may reflect renal damage. Moreover, ACE expression and activity were reduced in the kidney of the SHR at the same ages as for ACE2. 10 The reduction in both ACE2 and ACE in the SHR raises the issue of whether the ratio of Ang II to Ang-(1-7) is actually changed.
In the present findings by Kamilic et al., the authors find no change in ACE2 expression or activity in the kidneys of adult male stroke-prone SHR and transgenic (mRen2)27 rats with established hypertension, in comparison with their respective normotensive controls. Interestingly, the (mRen2)27 and Sprague-Dawley rats exhibited threefold higher renal ACE2 activity than the WKY rats or stroke-prone SHRs, emphasizing the strain differences in enzyme expression. It is not clear why the present findings in strokeprone SHR contrast with previous studies in this strain that report a reduction in ACE2 activity. 3 The Crackower study determined ACE2 mRNA and protein expression, but not enzyme activity, in renal tissue. 3 In addition to gene and protein expression, the Kamilic study assessed ACE2 activity in the kidney by a widely used method that measures the hydrolysis of the quenched fluorescent substrate Mca-Ala-Pro-Lys-DNP. 1 However, this substrate is not completely specific for ACE2, and the addition of an ACE2 inhibitor (and possibly other peptidase inhibitors) is necessary to verify activity. In this regard, Tikellis et al. 10 included an inhibitor of the enzyme prolyl oligopeptidase to prevent the hydrolysis of the substrate by this peptidase, which cleaves the Pro-X bond of various peptides. The two most widely used ACE2 inhibitors are MLN4760, a nonpeptide inhibitor no longer available from Millennium Pharmaceuticals and DX600, a large peptide inhibitor that may not be completely resistant to proteolytic degradation in tissue. To our knowledge, the studies by Kamilic are the first to assess ACE2 expression and activity in the kidney of the homozygous (mRen2)27 rat. This transgenic strain expresses the renin 2 (Ren2) gene and is considered as a hypertensive model of an elevated tissue renin-angiotensin system. Despite the reduced expression of renal renin in the (mRen2)27, the kidney exhibits higher Ang II content. 11 We assessed renal ACE2 in hemizygous mRen2.Lewis rats originated from the backcross of the (mRen2)27 into the Lewis background. 12 The male mRen2. Lewis rats also exhibit lower renin and higher Ang II in the renal cortex, but lower ACE2 activity as compared with the Lewis control rats. 11, 12 Indeed, the difference in the Ang II to Ang-(1-7) ratio between the Lewis and mRen2.Lewis rats reflects a similar change in the ACE to ACE2 ratio ( Figure 2 ). Figure 2 The Ang II to Ang-(1-7) and ACE to ACE2 ratios are higher in the renal cortex of the hypertensive male mRen2.Lewis rats (mRen2) in comparison with normotensive Lewis males. Data were adapted from Pendergrass et al., 12 used with permission by the American Journal of PhysiologyHeart and Circulatory Physiology.
Commentary
Moreover, chronic renin-angiotensin system blockade with an ACE inhibitor or AT1 antagonist that markedly reduces blood pressure in male mRen2.Lewis rats was associated with increased ACE2 mRNA expression and enzyme activity in the renal cortex. 12 However, Ang II-dependent activation of AT1 receptor reduces the expression of ACE2; 13 thus, the issue remains as to whether lower ACE2 activity increases Ang II or whether Ang II downregulates ACE2 in the kidneys of the mRen2.Lewis rats. Finally, the Kamilic study reports that the localization of ACE2 in the rat kidney is predominantly localized to the glomerulus with high expression in the visceral epithelial cells and with moderate expression in both endothelial and medial aspects of the renal vasculature, but no evidence for ACE2 in the proximal tubules. 1 The authors used the Millennium ACE2 antibody, in which staining was blocked by the immunogenic peptide, as well as showed comparable staining in both frozen and paraffin-embedded tissue sections. The absence of ACE2 in the tubular epithelium contrasts with other studies in human, mouse, sheep and rat that show ACE2 staining, mRNA expression or enzyme activity in the proximal tubules in addition to other cell types within the kidney. 5, 10, [14] [15] [16] Indeed, Warner et al. 17 found that ACE2 expressed in the MDCK tubular cells preferentially localizes or traffics to the apical aspect of the cell membrane, whereas ACE is found on both basolateral and apical areas consistent with in situ studies. Localization of ACE2 on the apical surface of the tubular epithelium would certainly favor a regulatory role for the enzyme in the processing of Ang II to Ang-(1-7) in the tubular fluid. Moreover, the intracellular localization of the enzyme within the kidney may provide a mechanism to buffer Ang II-dependent formation of reactive oxygen species. 18 The absence of immunoreactive ACE2 on tubular epithelium of the rat kidney in the present study is not clear. Possibly, the various ACE2 antibodies may recognize different molecular forms of the enzyme that could be present in the kidney and other tissues. Alternatively, different incubation or permeabilization conditions may have a significant influence on antibody recognition of ACE2. As with other components of the renin-angiotensin-aldosterone system, a standard antibody for ACE2 available for multiple species would be beneficial for comparative studies. Nevertheless, the present study emphasizes the need for continued research on ACE2, particularly in relation to ACE and perhaps other Ang IIforming enzymes such as chymase that generate the requisite substrate for ACE2. Indeed, it is evident that future studies require a more comprehensive inclusion of the components that comprise the distinct functional arms of the renin-angiotensin-aldosterone system. 19 
